Bladder Cancer Clinical Trial
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Abbreviated Inclusion Criteria:
Age 18 years or older, is willing and able to provide informed consent
Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
Life expectancy > 12 weeks
ECOG performance status of 0-1
Abbreviated Exclusion Criteria:
History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
History of severe autoimmune disease
Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 32 Locations for this study
Scottsdale Arizona, 85258, United States
Duarte California, 91010, United States
Los Angeles California, 90007, United States
Los Angeles California, 90048, United States
Los Angeles California, 90404, United States
Orange California, 92868, United States
Sacramento California, 95817, United States
Miami Florida, 33136, United States
Ocala Florida, 34474, United States
Orlando Florida, 32835, United States
Columbus Georgia, 31904, United States
Chicago Illinois, 60637, United States
Louisville Kentucky, 40202, United States
New Orleans Louisiana, 70121, United States
Omaha Nebraska, 68130, United States
Bronx New York, 10461, United States
Cleveland Ohio, 44122, United States
Toledo Ohio, 43614, United States
Pittsburgh Pennsylvania, 15232, United States
Greenville South Carolina, 29605, United States
Germantown Tennessee, 38138, United States
Nashville Tennessee, 37203, United States
San Antonio Texas, 78229, United States
Salt Lake City Utah, 84112, United States
Fairfax Virginia, 22031, United States
Milwaukee Wisconsin, 53226, United States
Seogu Busan, 49201, Korea, Republic of
Ilsandong-gu Goyang-si, Gyeonggi-do, 10408, Korea, Republic of
Seongnam-si Bundan-gu Kyunggi-do, 13620, Korea, Republic of
Gangnam-gu Seoul, 06351, Korea, Republic of
Seodaemun-gu Seoul, 03722, Korea, Republic of
Songpa-gu Seoul, 05505, Korea, Republic of
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.